康德沙坦用于治疗偏头痛:一个范围审查
Ena Elizabeth L Naoe1, Mykha Marie B Tabuzo1, Roland Dominic G Jamora2
1Division of Adult Neurology, Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila 1000, Philippines.
Clinical therapeutics
|June 26, 2025
概括
坎德沙坦是一种血管激素受体阻断剂,在偏头痛预防方面表现有前途,特别是在高血压患者中. 这种治疗是有效的,耐受性很好,并且可能提供一个具有成本效益的选择.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 偏头痛是全球残疾的主要原因之一.
- 由于严重的健康和财务影响,有效的治疗非常重要.
- 坎德沙坦是一种血管激素受体阻塞剂,正在探索偏头痛管理.
研究的目的:
- 审查坎德沙坦在偏头痛治疗中的有效性和安全性.
- 评估candesartan作为替代偏头痛治疗的潜力.
主要方法:
- 进行了对现有文献的范围审查.
- 该审查遵循系统性审查的首选报告项目和范围审查的元分析 (PRISMA-ScR) 的指导方针.
主要成果:
- 包括三十八篇文章,表明candesartan在偏头痛预防方面的有希望的结果.
- 特别是在并发性高血压患者中,注意到有效性,与已知治疗方法 (如β-阻塞剂) 相比.
- 益处包括减少头痛天数和偏头痛时间,具有良好的耐受性和每天服用一次剂量.
结论:
- 坎德沙坦为偏头痛治疗提供了一种安全有效的选择.
- 需要进一步研究急性攻击的使用,剂量反应,长期安全性和成本效益.
相关概念视频
Dose-Response Relationship: Potency and Efficacy
5.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
524
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524
Antihypertensive Drugs: Angiotensin II Receptor Blockers
942
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
942
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
704
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
704
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
227
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
227
Antihypertensive Drugs: Direct Renin Inhibitors
845
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
845


